Otros idiomas Sensei Biotherapeutics, Inc.

Acciones

SNSE

US81728A1088

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 28/06/2024			Varia. Cinco días.	Varia. 1 de enero.
0,6201 ^USD	-6,74 %		-5,90 %	-10,39 %

14/05	SENSEI BIOTHERAPEUTICS, INC. : Stephens Inc. mantiene su recomendación de compra	ZM
09/05	Sensei Biotherapeutics, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Sensei Biotherapeutics : Bio SNS-101 Data Webcast	04/06
Sensei Biotherapeutics : Company Presentation June 2024	01/06
ASCO 2024: Topline SNS-101 Dose Escalation Data	01/06
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference	30/05
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101	23/05
Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	09/05
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	24/04
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	24/04
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference	09/04
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment	04/04
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	04/04
Sensei Biotherapeutics : Company Presentation April 2024	02/04
Sensei Biotherapeutics, Inc. Announces Resignation of Erin Colgan as Chief Financial Officer, Effective April 10, 2024	02/04
North American Morning Briefing : Stocks Set for -2-	28/03
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium	22/03
Keystone Symposia 2024: Preclinical data for SNS-101	21/03
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences	06/03
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	28/02
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

SENSEI BIOTHERAPEUTICS : Tercer trimestre mixto; pero el colchón de liquidez permanece intacto

10 de noviembre 2022 a las 12:59